

INMUNOTERAPIA


CARLOS FERRER ALBIACH
DIRECTOR INSTITUTO ONCOLOGICO CONSORCIO HOSPITALARIO DE CASTELLON
PROFESOR ASOCIADO UNIVERSIDAD CARDENAL HERRERA CEU

5-8 de noviembre



p17.grupoaran.com

NSCLC Lymphocytes in tumor & stroma



Al-Shibli KI, et al.
CCR 2008



Contents lists available at ScienceDirect

Curr Probl Cancer

journal homepage: www.elsevier.com/locate/cpcancer



Systematic review of case reports on the abscopal effect




Yazan Abuodeh, MD, Puja Venkat, MD,
Sungjune Kim, MD, PhD

46 casos
13% SBRT ,1 dosis única
5 con inmunomoduladores

5-8 de noviembre de 2017

www.alatro2017.grupoaran.com



ENSAYOS RT-INMUNOTERAPIA

Category	Examples of Immune Rx	Disease Sites	Phase	Number of Current Studies
Check point Inhibitors	Anti-CTLA-4	Cervix, Melanoma, Head & Neck, Pancreas, Liver, and Lung	I/II/III	19
	Anti-PD-1/anti-PD-L1	Esophageal, NSCLC, Malignant Glioma, Melanoma (Brain metastases), Invasive Bladder, Oligometastatic Breast, H&N, Pancreatic and Gastric, Colorectal, Follicular Lymphoma	I/II/III	101
Cytokines	IL-2, IFN, GM-CSF and TGF- β Blockade	Metastatic Breast, NSCLC, Glioblastoma, Follicular Lymphoma and Pancreas	II	6
Cell Therapy	CAR T cells (Anti BCMA, CD19, CD-30, TAI-meso, EGFRvIII, mesothelin, CD22)	B-Cell Lymphomas, Pancreas, Glioblastoma, Cervix, Ovarian and Lung. ALL, NHL Large Cell and Follicular Lymphomas	I/II	8
Vaccines	AdV-tk, Sipuleucel-T	Prostate and Pancreas	I/II/III	5

??????????

- DOSIS?
- FRACCIONAMIENTO?
- CAMBIO DEL PARADIGMA DE PTV?

5-8 de noviembre de 2017

www.alatro2017.grupoaran.com

